The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Adult participants ≥19 years of age
Diagnosis of moderate-to-severe plaque psoriasis
Candidate for phototherapy or systemic therapy
Will begin deucravacitinib according to approved product label
Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)
The study population will include adult patients in Korea who have been diagnosed with moderate-to-severe plaque psoriasis and have been prescribed treatment with deucravacitinib according to the approved product label.
Cohort
Prospective
Deucravacitinib
DrugAs per product label
Number of participants with adverse events (AEs)
Number of participants with adverse drug reactions (ADRs)
Number of participants with serious adverse events (SAEs)
Number of participants with serious adverse drug reactions (SADRs)
Proportion of participants with static Physician Global Assessment (sPGA) of 0 or 1
Number of participants achieving Psoriasis Area and Severity Index (PASI) 75 (at least a 75% improvement in PASI score from baseline)
Click on the lead sponsor to view all of their trials.
